Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: an overview of systematic reviews
S Zhang, J Wang, X Li, H Zhang - Therapeutic Advances in …, 2024 - journals.sagepub.com
Background: Some systematic reviews (SRs) on triple therapy (consisting of long-acting β2-
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
[HTML][HTML] Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: an overview of systematic reviews
S Zhang, J Wang, X Li, H Zhang - Therapeutic Advances in …, 2024 - ncbi.nlm.nih.gov
Background: Some systematic reviews (SRs) on triple therapy (consisting of long-acting β 2-
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: an overview of systematic reviews.
S Zhang, J Wang, X Li, H Zhang - Therapeutic Advances in …, 2024 - search.ebscohost.com
Abstract Background: Some systematic reviews (SRs) on triple therapy (consisting of long-
acting β< sub> 2</sub>-agonist, long-acting muscarinic antagonist, and inhaled …
acting β< sub> 2</sub>-agonist, long-acting muscarinic antagonist, and inhaled …
Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: an overview of systematic reviews
S Zhang, J Wang, X Li, H Zhang - … advances in respiratory …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Some systematic reviews (SRs) on triple therapy (consisting of long-acting β 2-
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …